Chinese Japanese Germany Korea

Tofacitinib citrate

Description In vitro In vivo References
Tofacitinib citrate
Tofacitinib citrate structure
Chemical Name:
Tofacitinib citrate
Xeljanz;CP 690500-10;CP 690550-10;Tofacitinib API;CP-690550 citrate;Tofacitinib citrate;Tasocitinib citrate;Tofacititinib cirate;Tofacitinib Citratet;Xeljanz(tofacitinib)
Molecular Formula:
Formula Weight:
MOL File:

Tofacitinib citrate Properties

storage temp. 
room temp
DMSO: soluble5mg/mL (clear solution; warmed)
white to beige


WGK Germany  3

Tofacitinib citrate price More Price(6)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Sigma-Aldrich PZ0017 Tofacitinib citrate ≥98% (HPLC) 540737-29-9 5mg $97.3 2018-11-13 Buy
Sigma-Aldrich PZ0017 Tofacitinib citrate ≥98% (HPLC) 540737-29-9 25mg $393 2018-11-13 Buy
Cayman Chemical 11598 CP 690,550 ≥98% 540737-29-9 10mg $124 2018-11-13 Buy
Cayman Chemical 11598 CP 690,550 ≥98% 540737-29-9 5mg $65 2018-11-13 Buy
Cayman Chemical 11598 CP 690,550 ≥98% 540737-29-9 25mg $293 2018-11-13 Buy

Tofacitinib citrate Chemical Properties,Uses,Production


Tofacitinib citrate is a king of drugs developed by the US pharmaceutical company Pfizer for treating rheumatoid arthritis, trade name Xeljanz, for the treatment of methotrexate inadequate response or intolerance to severe active rheumatoid arthritis (RA) in adult patients. This product is a Janus kinase inhibitor, administered twice daily.
November 6, 2012, the US Food and Drug Administration (FDA) and Pfizer jointly announced Tofacitinib citrate is approved for the treatment of methotrexate inadequate response or intolerance to severe active rheumatoid joints arthritis (RA) in adult patients.
Xeljanz can be used as monotherapy or in combination with methotrexate or other non-biological disease-modifying antirheumatic drugs (the DMARD) in combination. This medicine should not be in combination with biological DMARD or strong immunosuppressants (such as cyclosporine and azathioprine). Xeljanz is approved by the daily dose of 2 times, each time 5mg.
Seven clinical trials evaluated the safety and efficacy of Tofacitinib citrate in moderate to severe active RA in adult patients. In all tests, compared with patients receiving placebo, patients receiving Xeljanz treatment showed significant improvement in clinical response and physical function.
In Clinical trials, the most common adverse events were upper respiratory tract infection, headache, diarrhea, nasal congestion, sore throat, and nasopharyngitis.
Using Xeljanz was associated with an increased risk of serious infections, including opportunistic infections, tuberculosis, cancer and lymphoma. Xeljanz product label attaches boxed warning on these security risks. Xeljanz treatment is also associated with reducing blood cell counts and increasing cholesterol and liver enzyme values.
In order to study Xeljanz long-term impact on heart disease, cancer and severe infections, FDA requires for a post-marketing study, which will evaluate two doses of Xeljanz (Tofacitinib citrate) therapy, and accept a integration of another group of patients approved by the treatment as a control.

In vitro

CP-690550 is a specific, orally inhibitor of JAK3, it is 20-to 100-fold less potent for JAK2 and JAK1 with IC50 of 20 nM and 112 nM, respectively. CP-690550 doesn't have potent activity against 30 other kinases (all median IC50 > 3000 nM). CP-690,550 inhibits IL-2–induced proliferation with 30-fold greater potency than its effects on GM-CSF–induced proliferation. CP-690550 effectively inhibits a murine mixed lymphocyte reaction (MLR) (IC50 = 91 nM).  CP-690550 potently inhibits IL-4 induced upregulation of CD23 (IC50=57 nM) and class II major histocompatibility complex (MHCII) expression (IC50=71 nM) on murine B cells. A recent research indicates low dose of CP-690550 accelerates the onset of experimental autoimmune encephalomyelitis by potentiating Th17 differentiation.

In vivo

In a murine model of heterotopic heart transplantation (DBA2 donor heart into C57/BL6 host), CP-690550 results in a dose-dependent increase in survival of transplanted hearts.The EC50 (drug concentration in blood at which 50% of mice will maintain their graft for >28 days) to be ~60 ng/mL.CP-690550 prevents rejection of allogeneic kidneys in nonhuman primate (NHPs, macaca fascicularis) (MST of 62 and 83 days for the 50 to 100 ng/ml groups and 200 to 400 ng/ml groups, respectively). Mice chronically dosed with CP-690550 (1.5-15 mg/kg/day) demonstrate dose and time-dependent alterations in lymphocyte subsets when examined by flow cytometry. The most dramatic change observed is a 96% reduction in splenic NK1.1+TCRb-cell numbers following 21 days of treatment. Delayed-type hypersensitivity (DTH) responses in sensitized mice are reduced in a dose-dependent manner following treatment with CP-690550 (1.87–30 mg/kg, s.c.).



ChEBI: A citrate salt obtained by combining equimolar amounts of tofacitinib and citric acid. Used to treat moderately to severely active Rheumatoid Arthritis.

Tofacitinib citrate Preparation Products And Raw materials

Raw materials

Preparation Products

Tofacitinib citrate Suppliers

Global( 233)Suppliers
Supplier Tel Fax Email Country ProdList Advantage
Lianyungang happen teng technology co., LTD
15950718863 CHINA 305 58
Shandonghaohong biotechnology Co.,ltd.
0635-6175299 13961496334
0635-6175299 CHINA 44 55
Henan DaKen Chemical CO.,LTD.
+86-371-55531817 CHINA 22043 58
Beijing Cooperate Pharmaceutical Co.,Ltd.
+86-10-60279497 +86(0)15646567669
+86-10-60279497 CHINA 1530 55
Henan Tianfu Chemical Co.,Ltd.
0371-55170693 CHINA 20786 55
Nanjing ChemLin Chemical Industry Co., Ltd.
025-83697070; CHINA 3015 60
+86 21 5161 9050/ 5187 7795
+86 21 5161 9052/ 5187 7796 CHINA 16534 60
TianYuan Pharmaceutical CO.,LTD
+86-755-23284190 13684996853
+86-755-23284190 CHINA 308 58
0086-13720134139 CHINA 956 58
Jinan Shengqi pharmaceutical Co,Ltd
86+15552594168 CHINA 339 58

View Lastest Price from Tofacitinib citrate manufacturers

Image Release date Product Price Min. Order Purity Supply Ability Manufacturer
2018-08-02 Tofacitinib citrate
US $2000.00 / KG 1KG 99% 100kg career henan chemical co
2018-07-30 Tofacitinib citrate
US $100.00 / KG 1KG 98% 100KG career henan chemical co
2018-07-25 Tofacitinib citrate
US $23.00 / G 10G 99% 1KG career henan chemical co

540737-29-9(Tofacitinib citrate)Related Search:

  • 3-((3R,4R)-4-Methyl-3-(Methyl(7H-pyrrolo[2,3-d]pyriMidin-4-yl)aMino)piperidin-1-yl)-3-oxopropanenitrile citrate
  • CP-690550 citrate
  • Tofacitinib (CP-690550) Citrate
  • Tofacitinib Citratet
  • 3-{4-Methyl-3-[Methyl-(7H-pyrrolo[2,3-d]pyriMidin-4-yl)-aMino]-piperidin-1-yl}-3-oxo-propionitrile
  • Tofacitinib API
  • Tofacitinib citric acid salt
  • (3r,4r)-4-Methyl-3-(Methyl-7h-pyrrolo(2,3-d)pyriMidin-4-ylaMino)-beta-oxo-1
  • Tofacititinib cirate
  • CP-690550 Citrate (Tofacitinib Citrate)
  • Tofacitinib (Tasocitinib, CP-690550)
  • Citrate Tropsch iMatinib
  • 1-Piperidinepropanenitrile, 4-Methyl-3-(Methyl-7H-pyrrolo[2,3-d]pyriMidin-4-ylaMino)-β-oxo-, (3R,4R)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)
  • Tofacitinib citrate (CP-690550)
  • Tofacitinib citrate
  • Tasocitinib citrate
  • Tasocitinib citric acid s...
  • Xeljanz
  • CP-690550 (Tofacitinib citrate)
  • 1-Piperidinepropanenitrile,4-Methyl-3-(Methyl-7H-pyrrolo[2,3-d]pyriMidin-4-ylaMino)-β-oxo-,(3R,4R)-,2-hydroxy-1,2,3-propanetricarboxylate
  • (3R,4R)-4-Methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-beta-oxo-1-piperidinepropanenitrile 2-Hydroxy-1,2,3-propanetricarboxylate Tofacitinib citrate(CP690550)
  • Tofacitinib citrate (3R,4R)-1-(Cyanoacetyl)-4-methyl-N-methyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-3-piperidinamine 2-hydroxy-1,2,3-propanetricarboxylate
  • (3R,4R)-4-Methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-bet
  • (3R,4R)-4-Methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-β-oxo-1-piperidinepropanenitrile citrate salt
  • 3-[(3R,4R)-4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile citrate salt
  • Tasocitinib citrate salt
  • Xeljanz(tofacitinib)
  • Tofacitinib-d3 Citrate
  • 540737-29-9
  • C16H20N6OC6H8O7
  • (3R,4R)-1-(Cyanoacetyl)-4-methyl-N-methyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-3-piperidinamine 2-hydroxy-1,2,3-propanetricarboxylate
  • (3R,4R)-4-Methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-beta-oxo-1-piperidinepropanenitrile 2-Hydroxy-1,2,3-propanetricarboxylate
  • CP 690500-10
  • CP 690550-10
  • 3-PiperidinaMine, 1-(cyanoacetyl)-4-Methyl-N-Methyl-N-1H-pyrrolo[2,3-d]pyriMidin-4-yl-, (3R,4R)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)
  • 3-{(3R,4R)-4-Methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-1-piperidinyl}-3-oxopropanenitrile 2-hydroxy-1,2,3-propanetricarboxylate (1:1)
  • Tofacitinib, Citrate Salt, >99%
  • Tofacitinib citrate, >=98%
  • 1-Piperidinepropanenitrile, 4-methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-beta-oxo-, (3R,4R)-, citrate
  • 3-{(3R,4R )-4-Methyl-3-[methyl(7H –pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}-3-oxopropanenitrile monocitrate
  • Tasocitinib citric acid salt
  • Tofacitinib Impurity 43
  • Tofacitinib citrate (540737-29-9)
  • Tofacitinib citrate (CP-690550 citrate)
  • C22H28N6O8
  • Inhibitors
  • JAK
  • STAT
  • API
  • Inhibitor
  • 54737-29-9
Copyright 2017 © ChemicalBook. All rights reserved